 HASBROUCK HEIGHTS, N.J., Oct. 11, 2021 GLOBE NEWSWIRE -- Nymox Pharmaceutical Corporation NASDAQ: NYMX the Company is pleased to report today a one-month update to shareholders as a follow-up to the September communication. The Company reinforces that its completion tasks for the important Fexapotide filing have advanced as anticipated and that substantial progress has ensued. 